1. Home
  2. YELP vs URGN Comparison

YELP vs URGN Comparison

Compare YELP & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yelp Inc.

YELP

Yelp Inc.

HOLD

Current Price

$22.81

Market Cap

1.2B

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$29.84

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YELP
URGN
Founded
2004
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2011
2016

Fundamental Metrics

Financial Performance
Metric
YELP
URGN
Price
$22.81
$29.84
Analyst Decision
Hold
Strong Buy
Analyst Count
6
7
Target Price
$29.17
$29.29
AVG Volume (30 Days)
1.3M
615.5K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
19.15
N/A
EPS
0.30
N/A
Revenue
$1,464,955,000.00
$1,128,000.00
Revenue This Year
$2.19
$129.09
Revenue Next Year
$2.34
$70.96
P/E Ratio
$80.93
N/A
Revenue Growth
3.75
N/A
52 Week Low
$19.60
$11.51
52 Week High
$35.99
$32.37

Technical Indicators

Market Signals
Indicator
YELP
URGN
Relative Strength Index (RSI) 44.16 62.40
Support Level $21.22 $26.67
Resistance Level $24.69 $30.34
Average True Range (ATR) 1.04 1.50
MACD 0.20 -0.14
Stochastic Oscillator 38.80 86.75

Price Performance

Historical Comparison
YELP
URGN

About YELP Yelp Inc.

Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: